Staar surgical board of directors unanimously believes alcon merger maximizes value for staar stockholders

Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), the global leader in phakic iols with the evo family of implantable collamer® lenses (evo icl™) for vision correction, today announced that it has filed its definitive proxy statement with the u.s. securities and exchange commission in connection with the company's pending merger with alcon (six/nyse: alc). staar will hold a special meeting of stockholders on october 23 at 8:30 a.m. (pacific time) to vote to adopt the.
ALC Ratings Summary
ALC Quant Ranking